An RNA sequencing dataset from a porcine immortalized pre-adipocyte cell line.
Riley SE., Thrower T., Lee S., Esteves CL., Donadeu FX.
Laboratory Study, published in Data Brief (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Data Brief (2025)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41079698
- PMCID
- PMC12514535
- DOI
- 10.1016/j.dib.2025.112074
Abstract (original English)
There is a significant need for livestock cell lines that can be robustly expanded in culture while maintaining their functional characteristics, both for use as in vitro models to understand animal physiology and for industrial applications such as in the emerging sector of cellular agriculture. Here we describe RNA sequencing datasets from a spontaneously immortalized pre-adipocyte line that was derived through serial passaging of porcine adipose-derived mesenchymal stromal cells (MSCs). This cell line, known as FaTTy, is unique in that it displays enhanced adipogenic capacity during long-term culture, characterised by a close to 100% differentiation efficiency and the ability to generate mature adipocytes. Bulk RNA sequencing was performed from FaTTy and parental MSCs. We present analysis of the raw files and bioinformatics analyses, including differential gene expression. These data provide valuable insight on the mechanisms of cell immortalization and the unique phenotype of the FaTTy cell line, with distinctive advantages as a prospective cell source for cultivated fat manufacture.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.